Article
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer.
Scientific reports - 3 Dec 2019
Nakao Keiko, Kobuchi Shinji, Marutani Shuhei, Iwazaki Ayano, Tamiya Akihiro, Isa Shunichi, Okishio Kyoichi, Kanazu Masaki, Tamiya Motohiro, Hirashima Tomonori, Imai Kimie, Sakaeda Toshiyuki, Atagi Shinji
Abstract excerpt
To investigate the exposure-safety relationships of afatinib in Japanese population, we performed population pharmacokinetics (PK) analysis of afatinib in Japanese advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutation. Plasma samples were collected at 0.5-1, 2-3, 8-12, and 24 h after oral afatinib (40 mg) administration on day 1 and day 8. Plasma afatinib concentrations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.